Moleculin Change In Working Capital from 2010 to 2024

MBRX Stock  USD 2.77  0.08  2.97%   
Moleculin Biotech Change In Working Capital yearly trend continues to be fairly stable with very little volatility. Change In Working Capital is likely to outpace its year average in 2024. Change In Working Capital is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. View All Fundamentals
 
Change In Working Capital  
First Reported
2015-09-30
Previous Quarter
-418 K
Current Value
1.3 M
Quarterly Volatility
1.1 M
 
Yuan Drop
 
Covid
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Depreciation And Amortization of 120.7 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.02. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
  
Check out the analysis of Moleculin Biotech Correlation against competitors.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Latest Moleculin Biotech's Change In Working Capital Growth Pattern

Below is the plot of the Change In Working Capital of Moleculin Biotech over the last few years. It is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. Moleculin Biotech's Change In Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
Change In Working Capital10 Years Trend
Pretty Stable
   Change In Working Capital   
       Timeline  

Moleculin Change In Working Capital Regression Statistics

Arithmetic Mean415,777
Coefficient Of Variation224.82
Mean Deviation591,495
Median322,790
Standard Deviation934,746
Sample Variance873.7B
Range3.8M
R-Value0.27
Mean Square Error873.5B
R-Squared0.07
Significance0.33
Slope55,963
Total Sum of Squares12.2T

Moleculin Change In Working Capital History

20241.7 M
20231.6 M
2022224 K
2021M
2020-41 K
2019-2.1 M
20181.6 M

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's Change In Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Working Capital1.6 M1.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.